Eli Lilly uses AI digital twin to speed tirzepatide manufacturing
Updated
Updated · The Wall Street Journal · May 2
Eli Lilly uses AI digital twin to speed tirzepatide manufacturing
5 articles · Updated · The Wall Street Journal · May 2
Lilly said the internally developed machine-learning system tested pressure and temperature changes to raise output of tirzepatide, the ingredient in Mounjaro and Zepbound, after earlier shortages.
The company did not disclose how much production time was cut or output increased, but its digital chief said the gains were large enough to reach many more patients.
The move reflects a wider pharma push into AI, where manufacturing and back-office efficiencies are delivering clearer benefits than drug discovery despite billions invested with companies including Nvidia.
AI promises to slash drug development costs. Will these massive savings be passed on to patients or simply boost corporate profits?
With billions invested in pharma AI, which company will be the first to bring a fully AI-discovered drug to market?
As AI becomes a 'black box' for drug discovery, how can regulators ensure these new medicines are truly safe for humans?
From Shortage to Market Dominance: Eli Lilly’s AI-Optimized Tirzepatide Manufacturing Drives Historic $1 Trillion Valuation
Overview
From late 2022 to 2026, Eli Lilly faced overwhelming demand for its diabetes and obesity drugs, Mounjaro and Zepbound, leading to an FDA-declared shortage. To meet this challenge, Lilly launched a multi-billion dollar manufacturing expansion, including a $6 billion facility in Alabama, and adopted advanced AI technologies like digital twins and machine learning to optimize production. These innovations boosted capacity by up to 40%, enabling the company to resolve the shortage and dramatically increase sales to $36.5 billion in 2025. This success propelled Lilly to a historic $1 trillion market valuation and signaled a broader industry shift toward AI-driven pharmaceutical manufacturing and supply chain resilience.